Techno Drugs Ltd has marked a significant milestone in Bangladesh’s pharmaceutical industry with the launch of South Asia’s first-ever single rod contraceptive implant.
The company, a pioneer in contraceptive implant manufacturing since 2019, is now the only producer in Bangladesh and one of only five companies worldwide to offer this innovative product, according to a press release.
The breakthrough followed extensive research and development, led by Techno Drugs Managing Director Shah Jalal Uddin Ahmed, a distinguished pharmacist with a global reputation. The new single rod implant is designed to replace the previous double rod implant, offering a more efficient and convenient contraceptive solution.
Techno Drugs operates South Asia’s sole facility dedicated to the production of these single rod implants, which has been purpose-built to ensure the highest standards of safety and quality. The “ETO Plant” produces implants that provide reliable, long-term contraceptive solutions for users.
This advancement not only strengthens Bangladesh’s position in the global reproductive healthcare market but also reduces the country’s reliance on imported contraceptives, while enhancing access to affordable and high-quality options.
“By establishing the first dedicated single rod implant plant in South Asia, we are setting new standards for accessibility, affordability, and innovation in reproductive healthcare,” said Techno Drugs Executive Director Arefeen Raafi Ahmed.
Since its founding in 1996, Techno Drugs has been at the forefront of innovation, particularly in oncology and hormonal medicine production. The company’s oncology manufacturing facility, operational for over 15 years, has been upgraded to meet international Good Manufacturing Practice (GMP) standards.
This upgrade will significantly expand production capacity and introduce a broader range of advanced oncology and hormonal therapies, meeting the increasing demand for affordable cancer treatments in Bangladesh and beyond.
Techno Drugs also holds a strong leadership position in the contraceptive sector, having pioneered the local manufacture of oncology medicines in 2010 and established South East Asia’s largest contraceptive injectable manufacturing plant in 2018. With a robust export network across Asia and Africa, the company remains committed to delivering high-quality healthcare solutions.
With ISO 9001:2015 certification and adherence to strict GMP standards, Techno Drugs continues to invest in research and innovation, working toward its vision of becoming a global leader in the pharmaceutical industry.
